These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

502 related items for PubMed ID: 23213854

  • 1. Encouraging generic use can yield significant savings.
    Zimmerman C.
    Find Brief; 2012 Nov; 15(8):1-3. PubMed ID: 23213854
    [Abstract] [Full Text] [Related]

  • 2. In Medicare Part D plans, low or zero copays and other features to encourage the use of generic statins work, could save billions.
    Hoadley JF, Merrell K, Hargrave E, Summer L.
    Health Aff (Millwood); 2012 Oct; 31(10):2266-75. PubMed ID: 23048108
    [Abstract] [Full Text] [Related]

  • 3. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM, Urmie JM, Farris KB, Doucette WR.
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [Abstract] [Full Text] [Related]

  • 4. Zero copayment for generic statins could save billions.
    Manag Care; 2013 Mar; 22(3):44. PubMed ID: 23610806
    [No Abstract] [Full Text] [Related]

  • 5. Cost variability of suggested generic treatment alternatives under the Medicare Part D benefit.
    Patel RA, Walberg MP, Tong E, Tan F, Rummel AE, Woelfel JA, Carr-Lopez SM, Galal SM.
    J Manag Care Spec Pharm; 2014 Mar; 20(3):283-90. PubMed ID: 24564812
    [Abstract] [Full Text] [Related]

  • 6. Impact of final short-fill rule on Medicare Part D costs and long-term care pharmacy dispensing.
    Bazalo G, Weiss RC.
    Consult Pharm; 2012 Apr; 27(4):269-73. PubMed ID: 22498986
    [Abstract] [Full Text] [Related]

  • 7. Free statins disrupt pharmacy benefit plans.
    Reinke T.
    Manag Care; 2012 Nov; 21(11):19-20. PubMed ID: 23236713
    [No Abstract] [Full Text] [Related]

  • 8. Favorable Formulary Placement of Branded Drugs in Medicare Prescription Drug Plans When Generics Are Available.
    Socal MP, Bai G, Anderson GF.
    JAMA Intern Med; 2019 Jun 01; 179(6):832-833. PubMed ID: 30882842
    [Abstract] [Full Text] [Related]

  • 9. Association of Industry Payments to Physicians With the Prescribing of Brand-name Statins in Massachusetts.
    Yeh JS, Franklin JM, Avorn J, Landon J, Kesselheim AS.
    JAMA Intern Med; 2016 Jun 01; 176(6):763-8. PubMed ID: 27159336
    [Abstract] [Full Text] [Related]

  • 10. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB, Frial T, Miller PS.
    Can J Clin Pharmacol; 2007 Jun 01; 14(2):e205-14. PubMed ID: 17556788
    [Abstract] [Full Text] [Related]

  • 11. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
    Dusetzina SB, Sarpatwari A, Carrier MA, Hansen RA, Keating NL, Huskamp HA.
    JAMA Intern Med; 2021 Dec 01; 181(12):1605-1611. PubMed ID: 34661600
    [Abstract] [Full Text] [Related]

  • 12. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG.
    Inquiry; 1993 Dec 01; 30(2):189-98. PubMed ID: 8314607
    [Abstract] [Full Text] [Related]

  • 13. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
    Pattanaprateep O, Pongcharoensuk P, Suvanakoot P, Kaojarern S.
    J Med Assoc Thai; 2010 Oct 01; 93(10):1223-31. PubMed ID: 20973328
    [Abstract] [Full Text] [Related]

  • 14. Trends in Use and Expenditures for Brand-name Statins After Introduction of Generic Statins in the US, 2002-2018.
    Lin SY, Baumann K, Zhou C, Zhou W, Cuellar AE, Xue H.
    JAMA Netw Open; 2021 Nov 01; 4(11):e2135371. PubMed ID: 34807258
    [Abstract] [Full Text] [Related]

  • 15. Brand Medications and Medicare Part D: How Eye Care Providers' Prescribing Patterns Influence Costs.
    Newman-Casey PA, Woodward MA, Niziol LM, Lee PP, De Lott LB.
    Ophthalmology; 2018 Mar 01; 125(3):332-339. PubMed ID: 28625684
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with independent pharmacy owners' satisfaction with Medicare Part D contracts.
    Zhang S, Doucette WR, Urmie JM, Xie Y, Brooks JM.
    Res Social Adm Pharm; 2010 Jun 01; 6(2):121-9. PubMed ID: 20511111
    [Abstract] [Full Text] [Related]

  • 17. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG.
    N Engl J Med; 2003 Dec 04; 349(23):2224-32. PubMed ID: 14657430
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Evolutions in both co-payment and generic market share for common medication in the Belgian reference pricing system.
    Fraeyman J, Verbelen M, Hens N, Van Hal G, De Loof H, Beutels P.
    Appl Health Econ Health Policy; 2013 Oct 04; 11(5):543-52. PubMed ID: 24062144
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.